Farmacoterapias paliativas para la disnea de la fibrosis quística
Referencias
References to studies excluded from this review
Additional references
American Thoracic Society. Dyspnoea: mechanisms, assessment and management: a consensus statement. American Journal of Respiratory and Critical Care Medicine 1999;159(1):321‐40.
Barnes H, McDonald J, Smallwood N, Manser R. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. Cochrane Database of Systematic Reviews 2016, Issue 3. [DOI: 10.1002/14651858.CD011008.pub2]
Bausewein C, Booth S, Higginson IJ. Measurement of dyspnoea in the clinical rather than the research setting. Current Opinion in Supportive and Palliative Care 2008;2(2):95‐9.
Bhatt J, Smyth A, Bertenshaw C. Nottingham Children's Hospital. Guideline for the management of patients with cystic fibrosis. www.nuh.nhs.uk/handlers/downloads.ashx?id=61166 (accessed prior to 26 June 2017).
Booth S, Bausewein C, Higginson I, Moosavi SH. Pharmacological treatment of refractory breathlessness. Expert Review of Respiratory Medicine 2009;3(1):21‐36.
Cystic Fibrosis Foundation. Hope in our hands. www.cff.org/UploadedFiles/aboutCFFoundation/AnnualReport/2010‐Annual‐Report.pdf (accessed 16 June 2014).
Cystic Fibrosis Foundation. About cystic fibrosis: what you need to know. www.cff.org/What‐is‐CF/About‐Cystic‐Fibrosis/ (accessed 16 June 2014).
Cystic Fibrosis Foundation. 2012 Annual Report. More tomorrows today. www.cff.org/About‐Us/Assets/2012‐Annual‐Report/ (accessed 16 June 2014).
Cohen SP, Dawson TC. Nebulized morphine as a treatment for dyspnoea in a child with cystic fibrosis. Pediatrics 2002;110(3):e38.
Dasenbrook EC, Konstan MW. Inhaled hypertonic saline in infants and young children with cystic fibrosis. JAMA 2012;307(21):2316‐7. [DOI: 10.1001/jama.2012.5853]
Deeks JJ, Higgins JPT, Altman DG, editor(s) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analysis. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Dellon EP, Chen E, Goggin J, Homa K, Marshall BC, Sabadosa KA, et al. Advance care planning in cystic fibrosis: current practices, challenges, and opportunities. Journal of Cystic Fibrosis 2016;15(1):96‐101.
Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947‐2003. European Respiratory Journal 2007;29(3):522‐6.
Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. New England Journal of Medicine 2006;354(3):241.
Ekström M, Nilsson F, Abernethy AA, Currow DC. Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review.. Ann Am Thorac Soc 2015 July;12(7):1079‐92.
Ekström M, Bajwah S, Bland JM, Currow DC, Hussain J, Johnson MJ. One evidence base; three stories: do opioids relieve chronic breathlessness?. Thorax Published Online First: 04 April 2017.
Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9.
Gautam V, Shafiq N, Singh M, Ray P, Singhal L, Jaiswal NP, et al. Clinical and in vitro evidence for the antimicrobial therapy in Burkholderia cepacia complex infections. Expert Review of Anti‐infective therapy 2015;13(5):629‐63.
Gift AG. Validation of a vertical visual analogue scale as a measure of clinical dyspnea. Rehabilitation Nursing 1989;14(6):323‐5.
Goggin J, Cohen RI. CF healthcare workers feel unprepared in providing suitable end of life care and desire more education: results of a nationwide survey. Journal of Cystic Fibrosis 2016;15(1):85‐9.
Graff GR, Stark JM, Grueber R. Nebulized fentanyl for palliation of dyspnoea in a cystic fibrosis patient. Respiration 2004;71(6):646‐9.
Hayes D, Anstead MI, Warner RT, Kuhn RJ, Ballard HO. Inhaled morphine for palliation of dyspnea in end‐stage cystic fibrosis. American Journal of Health‐system Pharmacy 2010;67(9):737‐40.
Henke MO, Ratjen F. Mucolytics in cystic fibrosis. Paediatric Respiratory Reviews 2007;8:24‐29.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60.
Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JPT, Deeks JJ, editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JPT, Altman DG, Sterne JAC, editors(s) on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JPT, Deeks JJ, Altman DG, editor(s) on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hommerding PX, Donadio MV, Paim TF, Marostica PJ. The Borg scale is accurate in children and adolescents older than 9 years with cystic fibrosis. Respiratory Care 2010;55(6):729‐33.
Janahi IA, Maciejewski SR, Teran JM, Oermann CM. Inhaled morphine to relieve dyspnea in advanced cystic fibrosis lung disease. Pediatric Pulmonology 2000;30(3):257‐9.
Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002;57(11):939‐44.
Kallet RH. The role of inhaled opioids and furosemide for the treatment of dyspnea. Respiratory Care 2007;52(7):900‐10.
Killian K. Dyspnea: mechanisms, measurement and management. In: Mahler DA, O’Donnell DE editor(s). History of dyspnoea. 2nd Edition. Boca Raton: Taylor & Francis, 2005:1–18.10.
Kleven DT, McCudden CR, Willis MS. Cystic fibrosis: newborn screening in America. Medical Laboratory Observer 2008;40(7):16‐27.
Linnemann RW, O'Malley PJ, Friedman D, Georgiopoulos AM, Buxton D, Altestien LL, et al. Development and evaluation of a palliative care curriculum for cystic fibrosis healthcare providers. Journal of Cystic Fibrosis 2015;15(1):90‐5.
Madge S, Sands D. End of Life: Have we got it right?. Journal of Cystic Fibrosis 2016;15(1):2‐3.
O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009;373(9678):1891‐904. [DOI: 10.1016/S0140‐6736(09)60327‐5]
Hospice, Palliative Care Federation of Massachusetts. Palliative sedation protocol: A report of the Standards and Best Practices Committee Hospice & Palliative Care Federation of Massachusetts April 2004. c.ymcdn.com/sites/www.hospicefed.org/resource/resmgr/hpcfm_pdf_doc/pal_sed_protocol_2004.pdf (accessed 16 June 2014).
Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnoea. American Journal of Respiratory and Critical Care Medicine 2012;185(4):435‐52. [DOI: 10.1164/rccm.201111‐2042ST]
Pattinson KT, Governo RJ, MacIntosh BJ, Russell EC, Corfield DR, Tracey I, et al. Opioids depress cortical centers responsible for the volitional control of respiration. Journal of Neuroscience 2009;29(25):8177‐86.
Peters MM, O'Donnell DE. Dyspnoea in chronic obstructive pulmonary disorder. In: Booth S, Dudgeon D editor(s). Dyspnoea in advanced disease:a guide to clinical management. Vol. 74, Oxford: Oxford University Press, 2006.
Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire‐Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135(6):1610‐8.
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Robinson W. Palliative care in cystic fibrosis. Journal of Palliative Medicine 2000;3(2):187‐92.
Sands D, Repetto T, Dupont LJ, Eksterowicz K, Catastini P, Madge S. End of life care for patients with cystic fibrosis. Journal of Cystic Fibrosis 2011;10(Suppl 2):S37‐S44.
Simon ST, Niemand AM, Benalia H, Voltz R, Higginson IJ, et al. Acceptability and preferences of six different routes of drug application for acute breathlessness: a comparison study between the United Kingdom and Germany. Journal of Palliative Medicine 2012;15(12):1374‐81.
Sterne JAC, Egger M, Moher D, editor(s) on behalf of the Cochrane Bias Methods Group. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). Cochrane Handbook forSystematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Tait P, Morris B, To T. Core palliative medicines: meeting the needs of non‐complex community patients. Australian Family Physician 2014;43(1):29‐32.
Torpy JM, Lynm C, Glass RM. Cystic fibrosis. JAMA 2009;302(10):1130. [DOI: 10.1001/jama.302.10.1130.]
UK Cystic Fibrosis Registry. Annual data report 2013. www.cysticfibrosis.org.uk/media/598466/annual‐data‐report‐2013‐jul14.pdf (accessed 31 July 2015).
Weinberger M. Airways reactivity in patients with CF. Clinical Reviews in Allergy and Immunology 2002;23(1):77.
WHO Genomic Resource Centre. Genes and human diseases: cystic fibrosis. www.who.int/genomics/public/geneticdiseases/en/index2.html (accessed prior to 06 April 2017).
References to other published versions of this review
Jaiswal N, Singh M, Agarwal A, Thumburu KK. Drug treatments for breathlessness in end‐stage cystic fibrosis. Cochrane Database of Systematic Reviews 2015, Issue 9. [DOI: 10.1002/14651858.CD011855]
Characteristics of studies
Characteristics of excluded studies [ordered by study ID]
| Study | Reason for exclusion |
| This was a small cross‐over study where first‐arm data were not available. |
Figuras y tablas -
Figure 1
Study flow diagram.
